A Multicenter, Open-Label Study to Assess the Tolerability and Safety of a Single, Subcutaneous Administration of Ecallantide in Children and Adolescents With Hereditary Angioedema

The objective of this study is to evaluate the safety and tolerability of a single Subcutaneous (SC) dose of Ecallantide in children and adolescents with Hereditary Angioedema (HAE).

Start Date01 Aug 2013

Sponsor / Collaborator

NYU Langone Health

[+1]

NCT01253382 / WithdrawnPhase 2/3

A 3-Part Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Subcutaneous Ecallantide in Prepubertal Paediatric Patients Experiencing Acute Attacks of Hereditary Angioedema (HAE)

The primary objective of this study is:
assess the safety and tolerability of ecallantide in paediatric patients for acute attacks of HAE
The secondary objectives are:
evaluate the pharmacokinetic profile of ecallantide in paediatric patients treated for acute attacks of HAE
assess the efficacy of ecallantide in paediatric patients treated for moderate to severe acute attacks of HAE

Start Date01 Jun 2012

Sponsor / Collaborator

Shire Plc

NCT01343823 / TerminatedPhase 2

Evaluation of Ecallantide for the Acute Treatment of Angiotensin Converting Enzyme Inhibitor Induced Angioedema

A double-blind, randomized, controlled trial comparing the safety and effectiveness of conventional therapy with ecallantide to conventional therapy with placebo.

Start Date01 Jun 2011

Sponsor / Collaborator

Shire Plc

100 Clinical Results associated with Ecallantide

100 Translational Medicine associated with Ecallantide

100 Patents (Medical) associated with Ecallantide

144

Literatures (Medical) associated with Ecallantide

01 Aug 2024·JOURNAL OF BIOTECHNOLOGY

Extension of the circulatory half-life of recombinant ecallantide via albumin fusion without loss of anti-kallikrein activity

Article

Author: Eltringham-Smith, Louise J ; Bhakta, Varsha ; Shirobokov, Valerie ; Sheffield, William P ; Al-Adimi, Ghofran

Ecallantide comprises Kunitz Domain 1 of Tissue Factor Pathway Inhibitor, mutated at seven amino acid positions to inhibit plasma kallikrein (PK). It is used to treat acute hereditary angioedema (HAE). We appended hexahistidine tags to the N- or C-terminus of recombinant Ecallantide (rEcall) and expressed and purified the resulting proteins, with or without fusion to human serum albumin (HSA), using Pichia pastoris. The inhibitory constant (K_i) of rEcall-H6 or H6-rEcall for PK was not increased by albumin fusion. When ¹²⁵I-labelled rEcall proteins were injected intravenously into mice, the area under the clearance curve (AUC) was significantly increased, 3.4- and 3.6-fold, for fusion proteins H6-rEcall-HSA and HSA-rEcall-H6 versus their unfused counterparts but remained 2- to 3-fold less than that of HSA-H6. The terminal half-life of H6-rEcall-HSA and HSA-H6 did not differ, although that of HSA-rEcall-H6 was significantly shorter than either other protein. Receptor Associated Protein (RAP), a Low-density lipoprotein Receptor-related Protein (LRP1) antagonist, competed H6-rEcall-HSA clearance more effectively than intravenous immunoglobulin (IVIg), a neonatal Fc receptor (FcRn) antagonist. HSA fusion decreases rEcall clearance in vivo, but LRP1-mediated clearance remains more important than FcRn-mediated recycling for rEcall fusion proteins. The properties of H6-rEcall-HSA warrant investigation in a murine model of HAE.

22 Jan 2024·Allergy and asthma proceedings

Real-world reporting rates of administration-site reactions with on-demand treatment of hereditary angioedema attacks

Article

Author: Frade, Joao P ; Tachdjian, Raffi ; Audhya, Paul K ; Savic, Sinisa ; Fasehun, Marie ; Fridman, Moshe

Background: Hereditary angioedema (HAE) is characterized by recurrent and unpredictable episodes of subcutaneous and/or submucosal swelling. Objective: To characterize the real-world treatment burden associated with existing on-demand therapies, we analyzed administration-site adverse drug reactions (ADR) associated with approved on-demand HAE therapies reported in the U.S. Food and Drug Administration's (FDA) Adverse Event Reporting System (FAERS). Methods: We searched the FAERS database from October 1, 2009, to March 31, 2022, for reports of all FDA-approved on-demand therapies for HAE: plasma-derived C1-inhibitor (pdC1-INH), ecallantide, icatibant, and recombinant C1-inhibitor (rhC1-INH). ADRs in which the drug was listed as the “primary suspect” were recorded for each drug. ADR preferred terms were grouped into 18 ADR domains based on semantic and/or clinical similarity, and the number of reports for each drug was calculated per year from the time of approval through March 2022, and descriptive results were presented. Preferred terms associated with administration-site ADRs identified from clinical trials and denoted on approved HAE drug U.S. package inserts were examined in a complementary analysis. Results: The highest reported rates of administration-site ADRs per year were site pain (17.9 reports per year), site erythema (7.4 per year), and site swelling (6.7 per year). RhC1-INH was the only drug for which access-site complications and/or malfunctions were reported (9.5 per year). PdC1-INH had the highest rate of incorrect route of product administration (3.7 per year). PdC1-INH showed statistically significant elevated reporting rate of injection-site reactions (reporting odds ratio [ROR] 3.59 [2.36‐5.46]; empirical Bayesian geometric mean [EBGM] 1.97 [1.39]). Icatibant and rhC1-INH showed a statistical trend toward an increased reporting rate of administration-site reactions. Conclusion: Real-world data from FAERS were generally consistent with adverse events reported in clinical trials and suggest that patients experience substantial treatment burden associated with FDA-approved parenteral on-demand therapies for HAE attacks. It should be noted that ADR rates are not exposure adjusted and are based on spontaneous reporting.

01 Jan 2024·Bioorganic chemistry

Design, expression and biological evaluation of DX-88mut as a novel selective factor XIa inhibitor for antithrombosis

Article

Author: Wang, Weihao ; Li, Zhengyang ; Sun, Feilong ; Li, Yitong ; Guo, Wei ; Kong, Yi

Thrombotic diseases, such as myocardial infarction, stroke, and deep vein thrombosis, severely threaten human health, and anticoagulation is an effective way to prevent such illnesses. However, most anticoagulant drugs in the clinic have different bleeding risks. Previous studies have shown that coagulation factor XI is an ideal target for safe anticoagulant drug development. Here, we designed the FXIa inhibitory peptide DX-88mut by replacing Loop1 (DGPCRAAHPR) and Loop2 (IYGGC) in DX-88, which is a clinical drug targeting PKa for the treatment of hereditary angioedema, using Loop1 (TGPCRAMISR) and Loop2 (FYGGC) in the FXIa inhibitory peptide PN2KPI, respectively. DX-88mut selectively inhibited FXIa against a panel of serine proteases with an IC₅₀ value of 14.840 ± 0.453 nM, dose-dependently prolonged APTT in mouse, rat and human plasma, and potently inhibited FeCl₃-induced carotid artery thrombosis in mice at a dose of 1 µmol/kg. Additionally, DX-88mut did not show a significant bleeding risk at a dose of 5 µmol/kg. Taken together, these results show that DX-88mut is a potential candidate for the development of a novel antithrombotic agent.

News (Medical) associated with Ecallantide

18 Mar 2024

·www.biospace.com

Fulcrum Therapeutics Appoints Patrick Horn M.D., Ph.D., as Chief Medical Officer

Industry veteran with late-stage clinical development, medical affairs, and regulatory experience; well-positioned to advance losmapimod towards a potential regulatory submission and approval Interim Chief Medical Officer, Iain Fraser, MBChB, DPhil, will continue to serve on Fulcrum’s executive leadership team as senior vice president (SVP) of early development CAMBRIDGE, Mass., March 18, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Fulcrum) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced the appointment of Patrick Horn, M.D., Ph.D., as chief medical officer, effective immediately. Dr. Horn is a seasoned executive with over 20 years of end-to-end drug development experience spanning multiple therapeutic areas, with an emphasis on rare diseases, across both large pharmaceutical and biotech companies. Interim chief medical officer, Iain Fraser, MBChB, DPhil, will continue to serve on Fulcrum’s executive leadership team as SVP of early development. Together, Drs. Horn and Fraser will be responsible for leading clinical development and overseeing regulatory strategy and execution. “I am very pleased to enrich our leadership team with Pat, an accomplished industry veteran who has successfully guided multiple therapies—including rare disease programs lacking existing regulatory pathways—through late clinical development, regulatory approval, and commercial launch,” said Alex C. Sapir, Fulcrum’s president and chief executive officer. “This is a key moment for Fulcrum as we continue to advance our Phase 3 REACH trial of losmapimod for patients with facioscapulohumeral muscular dystrophy and reinitiate our Phase 1b PIONEER trial of pociredir in sickle cell disease. We believe both Pat and Iain’s complementary expertise will be invaluable as we near several pivotal milestones for our two key clinical programs and advance our early-stage pipeline.” Dr. Horn added, "Joining Fulcrum is an exciting opportunity to bring potentially transformative therapies to patients especially as we advance towards near-term inflection points for losmapimod, a late-stage clinical program with first-to-market potential, and pociredir, a highly differentiated oral treatment option that may shift the current standard of care. Building on the encouraging clinical data generated to date, I, alongside Iain, look forward to working with the management team to deliver on the promise of Fulcrum’s differentiated pipeline of rare disease programs.” Dr. Patrick Horn is a distinguished professional with over 20 years of experience in the field of rare disease drug development, encompassing all stages from initial research to regulatory approval and commercial launch. His most recent role was as the Chief Medical Officer at HemoShear Therapeutics, specializing in rare metabolic diseases. Previously, he held the position of Chief Medical Officer at Albireo Pharma where he led the team that achieved marketing approvals in the US and Europe for Bylvay™ in progressive familial intrahepatic cholestasis (PFIC). Before his tenure at Albireo, he served as the Senior Vice President of Medical and Clinical Development at Orphan Technologies, directing the advancement of novel treatments for homocystinuria. Prior to this, he was the Chief Medical Officer at Tetraphase Pharmaceuticals, where he oversaw the clinical development of antibiotic candidates, including the program leading to the New Drug Application for eravacycline. Before Tetraphase, Dr. Horn led the clinical program at Dyax Corp. that resulted in the approval of Kalbitor® for the treatment of hereditary angioedema. Dr. Horn received his M.D., and Ph.D., from the University of Chicago and completed his pediatric residency at Boston Children’s Hospital. Prior to transitioning to industry, Dr. Horn was a practicing pediatrician at major academic institutions in Chicago. About Fulcrum Therapeutics Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrum’s two lead programs in clinical development are losmapimod, a small molecule in development for the treatment of facioscapulohumeral muscular dystrophy (FSHD), and pociredir (formerly known as FTX-6058), a small molecule designed to increase expression of fetal hemoglobin and in development for the treatment of sickle cell disease (SCD). Fulcrum uses proprietary technology to identify drug targets that can modulate gene expression to treat the known root cause of gene mis-expression. For more information, visit and follow us on Twitter/X (@FulcrumTx) and LinkedIn. Forward-Looking Statements This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this press release are forward-looking statements, including express or implied statements regarding advancement of losmapimod towards regulatory submission and approval;; reinitiation of the Phase 1b trial; advancement of Fulcrum’s early-stage pipeline; Fulcrum’s ability to deliver an FDA-approved therapy for FSHD patients; and the potential for pociredir to shift the standard of care;; among others. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in, or implied by, such forward-looking statements. These risks and uncertainties include, but are not limited to, risks associated with Fulcrum’s ability to continue to advance its product candidates in clinical trials; initiating and enrolling clinical trials on the timeline expected or at all; obtaining and maintaining necessary approvals from the FDA and other regulatory authorities; replicating in clinical trials positive results found in preclinical studies and/or earlier-stage clinical trials of losmapimod, pociredir and any other product candidates; obtaining, maintaining or protecting intellectual property rights related to its product candidates; managing expenses; managing executive and employee turnover, including integrating a new CMO; and raising the substantial additional capital needed to achieve its business objectives, among others. For a discussion of other risks and uncertainties, and other important factors, any of which could cause Fulcrum’s actual results to differ from those contained in the forward-looking statements, see the “Risk Factors” section, as well as discussions of potential risks, uncertainties, and other important factors, in Fulcrum’s most recent filings with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent Fulcrum’s views as of the date hereof and should not be relied upon as representing Fulcrum’s views as of any date subsequent to the date hereof. Fulcrum anticipates that subsequent events and developments will cause Fulcrum’s views to change. However, while Fulcrum may elect to update these forward-looking statements at some point in the future, Fulcrum specifically disclaims any obligation to do so. Contact: Chris Calabrese LifeSci Advisors, LLC ccalabrese@lifesciadvisors.com 917-680-5608

Executive ChangePhase 1Phase 2Drug Approval

22 Jan 2024

·medcitynews.com

Ionis Rare Disease Drug Is Headed to FDA, But Forthcoming Data Will Decide Competitive Profile

An Ionis Pharmaceuticals drug has preliminary data showing it met the main goal of its pivotal test in a rare disease with only a handful of approved treatments. With these results in hand, Ionis is now preparing to submit its drug candidate for FDA review. However, the key data that will determine how competitive the drug could be won’t become available until later this year. The Ionis drug, donidalorsen, is in development for hereditary angioedema (HAE), an inherited disease that leads to swelling attacks throughout the body. When these attacks close off the airway, they can become life threatening. Ionis reported Monday that its subcutaneously injected drug met the main trial goal of reducing the rate of angioedema attacks dosed every four weeks or every eight weeks compared to a placebo. The drug was well tolerated by patients and no serious adverse events were reported in the treatment group, according to the Carlsbad, California-based company. Ionis did not provide additional details about donidalorsen’s safety or the reduction in HAE attacks, but said it plans to present the Phase 3 results at an upcoming medical meeting this year. In Phase 2 testing, the average reduction in HAE attacks compared to a placebo was 90% in weeks one to 17. Furthermore, Phase 2 results showed 92% of treated patients were attack free versus 0% in the placebo arm from weeks five to 17. “We are very pleased with the positive topline results from the Phase 3 OASIS-HAE study of donidalorsen,” Kenneth Newman, senior vice president, head of clinical development at Ionis, said in a prepared statement. “Based on these results and the durable efficacy and favorable safety data seen in the ongoing Phase 2 open-label extension study, we believe donidalorsen, if approved, could be an attractive new treatment option for patients with HAE, many of whom continue to experience unpredictable, painful and severe breakthrough attacks despite currently available prophylactic treatments.” Ionis’s drugs are based on antisense oligonucleotides, small pieces of DNA or RNA that bind to messenger RNA to stop the production of a disease-causing protein. Donidalorsen is designed to target the mRNA responsible for producing a protein called prekallikrein, a precursor to the kallikrein protein that contributes to HAE attacks. If Ionis can bring its HAE drug to the market, it would compete against Takeda Pharmaceutical’s Kalbitor, an injectable kallikrein inhibitor. Another Takeda HAE drug, Firazyr, blocks a different protein called bradykinin. BioCryst Pharmaceuticals has commercialized an oral kallikrein inhibitor branded as Orladeyo. KalVista Pharmaceuticals has reached Phase 3 testing with sebetralstat, an oral kallikrein inhibitor developed as an on-demand treatment for HAE attacks. KalVista expects to report preliminary Phase 3 data early this year. Ionis said the scientific meeting presentation of donidalorsen’s Phase 3 data will happen by mid-2024. That’s also the time frame for reporting results from the open-label extension of the Phase 3 test and the separate group of patients who have transitioned to the Ionis drug from another prophylactic. These are the key data that will determine how the Ionis drug could match up against the competition. In a note sent to investors Monday, Leerink Partners analyst Mani Foroohar wrote that these results will clarify whether donidalorsen’s commercial profile supports broad switching from other drugs or if it will be driven mainly by newly diagnosed patients. Ionis plans to handle U.S. commercialization of donidalorsen if it’s approved. European commercialization is in the hands of Otsuka Pharmaceutical. In December, Ionis struck a deal granting Otsuka those rights in exchange for a $65 million upfront payment. The deal makes Otuska responsible for European regulatory submissions. The Japanese drugmaker would owe Ionis milestone payments and royalties from its sales of the drug in Europe. Image by Getty Images

Phase 3Clinical ResultPhase 2License out/in

06 Dec 2023

·www.biopharmadive.com

Pharvaris shares spike as drug appears to prevent symptoms of rare disorder

Shares of Pharvaris rose by as much as 42% Wednesday morning after the Switzerland-headquartered biotechnology company reported positive data for its main experimental drug.Pharvaris has been testing the drug, known scientifically as deucrictibant, as a potential treatment for hereditary angioedema, a rare genetic disorder in which patients experience episodes, or attacks, of rapid and severe swelling. The company announced late last year that its therapy, when used on demand, significantly reduced the symptoms associated with these attacks in a mid-stage clinical trial.A separate, so-called proof-of-concept study named CHAPTER-1 has been evaluating whether the drug can also prevent attacks from happening. That appears to be the case, according to Pharvaris, which disclosed high-level results Wednesday.The study enrolled 34 participants who received each day either a placebo, a 20 mg dose of Pharvaris drug or 40 mg dose over 12 weeks. Researchers then documented how many attacks participants had. They found that compared to the placebo group, which experienced about two attacks per month, the monthly attack rate was 79% lower in the lower dose arm and nearly 85% lower in the higher dose arm.Additionally, Pharvaris said patients who received its drug experienced clinically meaningful improvement in the severity of their attacks, as well as a meaningful improvement on their quality of life. The company noted, too, that both doses of its drug appeared well-tolerated. There were no serious adverse events or severe treatment-emergent adverse events, nor did anyone drop out of the trial because of side effects.The safety findings may be especially important, given that, in August 2022, the Food and Drug Administration paused two trials of deucrictibant, including Chapter-1, following a review of nonclinical data. Pharvaris a month later said the FDA had asked for an additional long-term rodent toxicology study.By June of this year, the FDA agreed to allow the one trial testing Pharvaris drug as an on-demand treatment to continue. As of early November, the company was still trying to get the hold on Chapter-1 lifted.Pharvaris remains committed to resolving the U.S. clinical hold on deucrictibant for the prophylactic treatment of [hereditary angioedema], and we are on track to submit the non-clinical rodent data to the FDA by the end of the year, said CEO Berndt Modig in a recent statement.Alongside the clinical results, the company announced plans to raise $300 million from the offering of ordinary shares and pre-funded warrants.In the U.S., there are already a half-dozen approved medicines for hereditary angiodema. They include Takedas Takhzyro and Kalbitor, CSL Behrings Berinert and Haegarda, and BioCryst Pharmaceuticals Orladeyo. But, with the exception of Orladeyo, all those drugs are given as injections. Companies like Pharvaris and KalVista Pharmaceuticals see an opportunity for newer, oral options that many patients may view as more convenient.For Pharvaris to be competitive, it would need to exceed the bar set by BioCryst while also showing its drug is roughly as effective as currently available injections, according to Joseph Schwartz, an analyst at the investment firm Leerink Partners.Following the results announcement, Schwartz wrote in a note to clients that the data falls squarely within his teams bull case scenario for the drug. This attack rate reduction potentially positions deucrictibant much more favorably than Orladeyo in the commercial market, which has been selling well, he wrote. '

Clinical ResultClinical Study

100 Deals associated with Ecallantide

External Link

KEGG	Wiki	ATC	Drug Bank
D03931	Ecallantide	B06AC03	DB05311

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Hereditary Angioedema	US	Takeda Pharmaceuticals U.S.A., Inc.	01 Dec 2009

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Hereditary Angioedema Types I and II	Phase 2	US	Takeda Pharmaceuticals U.S.A., Inc.	01 Aug 2013
Angioedema	Phase 2	US	Shire Plc	01 Jun 2011
Blood Loss, Surgical	Phase 2	US	-	01 May 2007
Hemorrhage	Phase 2	US	-	01 May 2007
Retinal oedema	Phase 2	EU	Fovea Pharmaceuticals SA	-
Macular Edema	Phase 1	FR	Fovea Pharmaceuticals SA	01 Sep 2009
Retinal Vein Occlusion	Phase 1	FR	Fovea Pharmaceuticals SA	01 Sep 2009

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ASGCT2024	Not Applicable	Hereditary Angioedema	-	AAV8-DX88-HSA	ezcnygobsw(ysaklzwsxc) = bilmezvupp zrdogktkty (fuzzucbnrm ) View more	-	07 May 2024
NCT00448864 (CTgov)	Phase 2	Hemorrhage \| Blood Loss, Surgical	75	Ecallantide (Ecallantide - Low Dose Regimen)	phfjumimmf(itylqgofci) = alehfvogrl cirjytcknx (ycoootynjw, njsasdznaj - pwpymlcapi) View more	-	08 Jul 2015
NCT00448864 (CTgov)	Phase 2	Hemorrhage \| Blood Loss, Surgical	75	Ecallantide (Ecallantide - High Dose Regimen)	phfjumimmf(itylqgofci) = pgfqcpbali cirjytcknx (ycoootynjw, cycfqllfxh - cestarrwwm) View more	-	08 Jul 2015
NCT01036659 (Pubmed \| Ann Allergy Asthma Immunol) Manual	Phase 2	Angioedema	26	ecallantide	gptokbboov(oglmcvnubv) = aynlsowhjj iydxggoqxj (ejvcnyxoba )	Positive	01 Mar 2015
NCT01036659 (Pubmed \| Ann Allergy Asthma Immunol) Manual	Phase 2	Angioedema	26	Placebo	gptokbboov(oglmcvnubv) = umacpkwufl iydxggoqxj (ejvcnyxoba )	Positive	01 Mar 2015
AAAAI2014	Not Applicable	Hereditary Angioedema Type III C1 inhibitor protein level \| C1 inhibitor function \| C1Q level ... View more	1	Ecallantide	xpcvpazgwp(tyieqkoxsn) = The patient has had no side effects with ecallantide woykowwgzj (wkhbyaklyj )	Positive	01 Feb 2014
AAAAI2014	Not Applicable	Angioedema	50	Ecallantide 10mg	iedvpboobn(cnnnqncbas) = dwcgsxdfuc lyknktqmlb (odjcbknalf, -14.1% - 34.0%)	-	01 Feb 2014
AAAAI2014	Not Applicable	Angioedema	50	Placebo	iedvpboobn(cnnnqncbas) = rtojkhktnf lyknktqmlb (odjcbknalf )	-	01 Feb 2014
NCT01343823 (CTgov)	Phase 2	Angioedema	79	placebo	tijxkhkzzu(scewufmjsg) = sempyctryz hhlvfudtos (pwphtordpm, wbvcymbfeh - ouohpzqnhw) View more	-	18 Nov 2013
NCT00456508 (CTgov)	Phase 3	Hereditary Angioedema	147	ecallantide	ftpgzbvhtd(bqmfcocxwo) = ytapohknsl szpbtsphpq (ggchhibdzl, ckvkmmaunn - ymffbykbju) View more	-	28 Dec 2012
EDEMA (AAAAI2012)	Not Applicable	Hereditary Angioedema	98	Ecallantide 30 mg	vtmyvzirxt(aaraapoukl) = 1 anaphylactic reaction jpxpqyzmin (ssdvtanrpf ) View more	Positive	01 Feb 2012
AAAAI2012	Not Applicable	Hereditary Angioedema	144	Ecallantide	hvjcodnjlx(irjiglbdlv) = fyhkdwjjmu sgnhjmlrll (qomwtlagnc ) View more	Positive	01 Feb 2012
NCT00888940 (CONSERV-2, CTgov)	Phase 2	Hemorrhage \| Blood Loss, Surgical	243	Ecallantide (Ecallantide)	gsckroczdv(jpcuvdrvrh) = owvhqwerqs xscgejegfs (sycfafuzge, iwggjjelyk - mkooeyigyp) View more	-	17 Jan 2011
NCT00888940 (CONSERV-2, CTgov)	Phase 2	Hemorrhage \| Blood Loss, Surgical	243	Cyklokapron(R) (Cyklokapron(R))	gsckroczdv(jpcuvdrvrh) = cgoqqjdwln xscgejegfs (sycfafuzge, ktfmtqsdta - npcwageasl) View more	-	17 Jan 2011

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis